PROCEPT BioRobotics Corporation $PRCT Shares Bought by Swiss National Bank

Swiss National Bank lifted its holdings in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 2.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 99,600 shares of the company’s stock after buying an additional 2,500 shares during the period. Swiss National Bank owned approximately 0.18% of PROCEPT BioRobotics worth $5,803,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in PROCEPT BioRobotics by 107.2% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 76,376 shares of the company’s stock worth $4,450,000 after acquiring an additional 39,516 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of PROCEPT BioRobotics by 43.2% in the 1st quarter. Westfield Capital Management Co. LP now owns 748,557 shares of the company’s stock valued at $43,611,000 after purchasing an additional 225,894 shares during the last quarter. Evolutionary Tree Capital Management LLC boosted its holdings in shares of PROCEPT BioRobotics by 20.9% in the 1st quarter. Evolutionary Tree Capital Management LLC now owns 73,867 shares of the company’s stock valued at $4,303,000 after purchasing an additional 12,749 shares during the last quarter. Blair William & Co. IL boosted its holdings in shares of PROCEPT BioRobotics by 12.5% in the 1st quarter. Blair William & Co. IL now owns 470,286 shares of the company’s stock valued at $27,399,000 after purchasing an additional 52,392 shares during the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych acquired a new position in shares of PROCEPT BioRobotics in the 1st quarter valued at $932,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

Insiders Place Their Bets

In other news, Director Antal Rohit Desai sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $61.49, for a total value of $1,537,250.00. Following the transaction, the director owned 14,363 shares of the company’s stock, valued at approximately $883,180.87. This trade represents a 63.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders have sold 100,000 shares of company stock valued at $6,271,250. Company insiders own 17.40% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on PRCT. Oppenheimer initiated coverage on shares of PROCEPT BioRobotics in a report on Monday, July 7th. They set a “market perform” rating on the stock. Wall Street Zen raised shares of PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Wells Fargo & Company decreased their price target on shares of PROCEPT BioRobotics from $75.00 to $58.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Morgan Stanley reduced their target price on shares of PROCEPT BioRobotics from $71.00 to $68.00 and set an “overweight” rating for the company in a research note on Tuesday, July 15th. Finally, Stephens started coverage on shares of PROCEPT BioRobotics in a research note on Wednesday, July 9th. They issued an “overweight” rating and a $70.00 price target for the company. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, PROCEPT BioRobotics currently has an average rating of “Moderate Buy” and a consensus target price of $74.88.

PROCEPT BioRobotics Trading Down 2.1%

Shares of PRCT stock opened at $40.71 on Tuesday. The stock has a market cap of $2.27 billion, a price-to-earnings ratio of -26.26 and a beta of 1.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.86 and a current ratio of 9.21. The firm has a fifty day moving average of $54.36 and a 200-day moving average of $57.38. PROCEPT BioRobotics Corporation has a 52-week low of $37.12 and a 52-week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.06. The firm had revenue of $79.18 million during the quarter, compared to analysts’ expectations of $75.67 million. PROCEPT BioRobotics had a negative net margin of 30.60% and a negative return on equity of 23.73%. The company’s quarterly revenue was up 48.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.50) EPS. On average, equities research analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).